The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 2, 2008, Pages 150-156

  Cluny, Nina L ^a,c   Naylor, Robert J ^a   Whittle, Brian A ^b   Javid, Farideh A ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b Porton Down Science Park   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; DRONABINOL; SCOPOLAMINE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; LATENT PERIOD; MALE; MOTION; MOTION SICKNESS; NONHUMAN; PRIORITY JOURNAL; SHREW; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIEMETICS; CANNABIDIOL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MOTION SICKNESS; RECEPTOR, CANNABINOID, CB1; SHREWS; TETRAHYDROCANNABINOL; VESTIBULE, LABYRINTH; VOMITING;

SUNCUS MURINUS;

EID: 47749105712     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00253.x     Document Type: Article

References (42)

1. Spinks AB, Wasiak J, Villanueva EV, Bernath V. Scopolamine for preventing and treating motion sickness. Cochrane Database Syst Rev 2004 3 : CD002851.
2. Reason JT, Brand JJ. Motion Sickness. Academic Press, London, 1975.
3. James W. The sense of dizziness in deaf-mutes. Am J Otol 1882 4 : 239 54.
4. Kennedy RS, Graybiel A, McDonough RC, Beckwith FD. Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. NSAM-928, NASA Ord. No. R-P3, Naval School of Aviation Medicine, Pensacola, FL, May 25, 1965.
5. Reynolds TT. On the nature and treatment of seasickness. Lancet 1884 1 : 1161 2.
6. Sjoberg A. Experimental studies of the eliciting mechanism of sea sickness. Acta Otolaryngol 1929 13 : 343 7.
7. Wilpizeski CR, Lowry LD, Goldman WS. Motion-induced sickness following bilateral ablation of area postrema in squirrel monkeys. Laryngoscope 1986 96 : 1221 5.
8. Miller AD, Wilson VJ. Vestibular-induced vomiting after vestibulocerebellar lesions. Brain Behav Evol 1983 23 : 26 31.
9. Stoffregen TA, Smart LJ, Jr. Postural instability precedes motion sickness. Brain Res Bull 1998 47 : 437 48.
10. 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol 2003 285 : G566 76.
11. 1 receptors in the brainstem of the ferret. Gastroenterology 2001 121 : 767 74.
12. Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 2004 171 : 156 61.
13. 1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol 2001 430 : 49 58.
14. 9-Tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 2001 69 : 239 49.
15. Javid FA, Wright C, Naylor RJ, Whittle BA. The role of cannabinoids in the mediation of motion sickness in Suncus murinus. FENS Abstr 2002 1 : A142. 14.
16. Hoyle CHV, Hill J, Sanger GJ, Andrews PLR. Analysis of pancreatic polypeptide cDNA from the house musk shrew, Suncus murinus, suggests a phylogenetically closer relationship with humans than for other small laboratory animal species. Regul Pept 2003 114 : 137 44.
17. Colbert EH. Evolution of Vertebrates, 2nd edn. John Wiley & sons, New York, NY, 1969.
18. Hoyle CHV, Chakrabarti G, Pendleton NP, Andrews PLR. Neuromuscular transmission and innervation in the urinary bladder of the insectivore Suncus murinus. J Auton Nerv Syst 1998 69 : 31 8.
19. Javid FA, Naylor RJ. Variables of movement amplitude and frequency in the development of motion sickness in Suncus murinus. Pharmacol Biochem Behav 1999 64 : 115 22.
20. Ueno S, Matsuki N, Saito H. Suncus murinus as a new experimental model for motion sickness. Life Sci 1988 43 : 413 20.
21. Andrews P, Torii Y, Saito H, Matsuki N. The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol 1996 307 : 305 13.
22. Andrews P, Dovey E, Hockaday J, Hoyle CH, Woods AJ, Matsuki N. The development of the emetic reflex in the house musk shrew, Suncus murinus. Brain Res Dev Brain Res 2000 121 : 29 34.
23. Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav 2002 73 : 979 89.
24. Nakayama H, Yamakuni H, Higaki M, Ishikawa H, Imazumi K, Matsuo M et al. Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci 2005 98 : 396 403.
25. 9-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 2002 300 : 34 42.
26. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981 21 : 417S 27S.
27. Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 2004 174 : 254 9.
28. Billig I, Yates BJ, Rinaman L. Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol 2001 281 1243 55.
29. Leslie RA, Reynolds DJM. Functional anatomy of the emetic circuitry in the brainstem. In : Bianchi AL, Grelot L, Miller AD, King GL (eds). Mechanisms and Control of Emesis. Colloque INSERM, London, 1992 19 27.
30. Lang IM, Sarna SK, Shaker R. Gastrointestinal motor and myoelectric correlates of motion sickness. Am J Physiol 1999 277 : G642 52.
31. 9-tetrahydrocannabinol in apomorphine-induced emesis in the dog. Life Sci 1978 23 : 49 53.
32. Loewe S. Studies on the pharmacology and acute toxicity of compounds with marihuana activity. J Pharmacol Exp Ther 1946 88 : 154 61.
33. Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 1989 169 : 159 65.
34. 9-Tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001 24 : 198 203.
35. 9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 2004 488 : 201 12.
36. 9-Tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 2005 80 : 35 44.
37. Darmani NA, Janoyan JJ, Crim J, Ramirez J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol 2007 563 : 187 96.
38. Kennedy RS, Graybiel A, McDonough RC, Beckwith FD. Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. Acta Otolaryngol 1968 66 : 533 40.
39. 1 receptor protein in the rat vestibular nucleus complex and the effects of unilateral vestibular differentiation. Brain Research 2004 1021 : 264 71.
40. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001 22 : 565 72.
41. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002 54 : 161 202.
42. Andrews PL, Okada F, Woods AJ, Hagiwara H, Kakaimoto S, Toyoda M et al. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol 2000 130 : 1247 54.